Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

Many thanks to the Commissiongs, Jenene Thomas, and the rest of the staff for hosting todays ASM

A few things I came away with are - no matter how much I belly-ache, I believe this team is united, is trying their best to build a company unparalleled with any other in the speciality nerodegenerative disease niche, and is striving hard to hit key milestones that will advance their program further - its quite a bit different meeting the actual people in person who are working behind the scenes and are in the trenches on a daily basis...

That said, LymPro will get to market and it will have KOL support - looking for more firm developments throughout the remainder of 3Q15 - most definitely 4Q15. However, it will in all likelihood be used in conjunction with current PET diagnostic standards

ESS is the hot ticket item. It just may become the quintessential "Game Change" for AMBS, as its already advanced through Orphan and CLIA designations - has USDOD backing and support, and is ready to commence clinicals in 3 locations in 3Q15. IMHO, the hype and buzz around ESS primarily stole the show.

The NAS will be exceptionally important for AMBS and its ability to attract deeper pockets and potential alternate funding sources - with a uplisting, new doors will open and I believe that conversations have already taken place with institutionals and IB's. AMBS remains in a brutal race against the clock of getting funding vs. continued equity distribution.

AJMHO - JP